

Home | News A-Z | Health A-Z | Drugs A-Z | Medical Devices | Health Services | News Archive | Info / About



March 12, 2014

Search

1,253 people on this site  
powered by chartbeat

Other search tools: [Drugs](#) | [Health](#) | [News](#)

[Terms](#) | [Submit News](#) | [About](#) | [RSS](#)

Latest News

- RTI Surgical launches 2 new biological solutions at AAOS annual meeting in New Orleans
- Respicardia receives Best Innovation of 2014 award from CRT and CV Pipeline for remedē System
- Perrigo launches methazolamide tablets
- iCAD prices underwritten public offering of 2,400,000 shares of common stock
- Research report on the rapid medical diagnostic kits market
- Amedisys' net service revenue decreases 13.7% to \$303.5 million in Q4 2013
- Protein Metrics releases Byologic software to improve analytical quality
- First Edition: March 12, 2014
- EPFL sets up foundation to release antibiotic for tuberculosis
- N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis
- Precision and Agrivida enter into trait development collaboration based on precise gene modifications

Safari Power Saver  
Click to Start Flash Plug-in

## EPFL sets up foundation to release antibiotic for tuberculosis

Published on March 12, 2014 at 7:59 AM · No Comments

[Print PDF](#) | [Recommend](#) 1 | [Share](#) | [+1](#) | [Tweet](#) 6

Even though [tuberculosis](#) kills more than 1.5 million people every year, the market is not cost-effective for pharmaceutical companies. So EPFL is setting up a foundation to release an antibiotic developed in its own laboratories under EU funding.

Researchers from EPFL and the AN Bach Institute in Moscow have discovered a new and extremely promising antibiotic for tuberculosis, especially effective against multi-resistant strains of the disease, which are on the rise in Eastern Europe. The drug, developed as a European FP7 project, has proven very effective against the disease. In an article published in *EMBO Molecular medicine*, the researchers show that, when combined with other drugs, the new antibiotic, called "PBTZ169", can take down even the most resistant strains of tuberculosis bacteria. Following the publication, the researchers formed the IM4TB Foundation on their campus. Supported by EPFL, the foundation aims to bring the new treatment to the market. This unusual step was taken because traditionally, technology transfer from academia to the pharmaceutical industry doesn't work well with tuberculosis: development costs are too high and the affected countries are often barely able to maintain their own healthcare infrastructures.

With the IM4TB Foundation, EPFL intends to pick up the slack in the limitations of the industrial model. "The development of antibiotics is increasingly expensive and the countries most affected by tuberculosis are still emergent," says Benoit Lechartier, co-author of the PBTZ169 study. "The recent closure of the AstraZeneca research center in India illustrates the extent to which it is difficult for the pharmaceutical industry to invest in infectious diseases."

### Human trials in 2015

Located on the EPFL campus, the IM4TB Foundation plans to move onto human trials within a year, in collaboration with the University of Lausanne Hospitals (CHUV).

PBTZ169 shows much promise. It attacks the bacterium's strong point - the cell wall, which forms an impenetrable shield against antibiotics and the patient's immune system. "Our molecule makes the bacterium literally burst open," explains Stewart Cole, director of the study and head of EPFL's Global Health Institute.

### A cheap but formidable weapon against resistant strains

The researchers showed that PBTZ169 is extremely effective in tri-therapy, where it is combined with a standard drug, pyrazinamide, and a more recent one, bedaquiline - and both these drugs have already been approved by the EU and the FDA for multi-resistant strains. "This could be the winning strategy", says Cole. "These molecules attack different targets in the bacterium. By combining them, we drastically reduce the risk that it will mutate into more resistant forms."

[Continued on Next page >>](#)

Posted in: [Medical Research News](#) | [Medical Condition News](#) | [Pharmaceutical News](#)  
Tags: [AIDS](#), [Antibiotic](#), [Cell](#), [Drugs](#), [Healthcare](#), [HIV](#), [Infectious Diseases](#), [Pyrazinamide](#), [technology](#), [Tuberculosis](#)

## Pharmaceuticals Positions

[www.experteer.com/Pharmaceuticals](http://www.experteer.com/Pharmaceuticals)

Find top Pharmaceuticals Jobs in Europe. Sign up on Experteer® now!

← Prior News

[N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis](#)

Next News →

[First Edition: March 12, 2014](#)

Read in | [English](#) | [Español](#) | [Français](#) | [Deutsch](#) | [Português](#) | [Italiano](#) | [日本語](#) | [한국어](#) | [简体中文](#) | [繁體中文](#) | [Nederlands](#) | [Русский](#) | [Svenska](#) | [Polski](#)

Advertisement

Upload photos anytime, anywhere.

Sign Up

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Post a new comment

Login ...

Quirky Comment Title (optional)

Post

News-Medical.Net

Like

74,938 people like News-Medical.Net.

Facebook social plugin

The Medical News

Follow +1

+ 2,311

News-Medical.Net provides this medical information service in accordance with these [terms and conditions](#). Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

- [News A to Z](#) | [Drugs A to Z](#) | [Health A to Z](#) | [Medical Devices](#) | [Medical / Health Services](#)
- [Newsletters](#) | [News Archive](#) | [Medical News Tweets](#) | [Information](#) | [Subscribe](#)

Other AZoNetwork Websites

- [AZoM.com](#) • [AZoNano.com](#) • [AZoOptics.com](#) • [AZoCleantech.com](#) • [AZoSensors.com](#)
- [AZoRobotics.com](#) • [AZoMining.com](#) • [AZoBuild.com](#) • [AZoQuantum.com](#) • [News-Medical.Net](#)

follow us on **FREE** Condition-Specific APP's

Mobile Apps